- Status:
- Red
- Decision Date:
- March 2019
Comments
RED1,2,3: NICE TA562 -with binimetinib for the treatment of adults with unresectable or metastatic BRAF V600 mutation positive melanoma.
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again